Di Benedetto F, Magistri P, Di Sandro S, Sposito C, Oberkofler C, Brandon E, et al. Safety and efficacy of robotic vs open liver resection for hepatocellular carcinoma. JAMA Surg. 2023;158(1):46–54.

Article  PubMed  Google Scholar 

Chavda V, Zajac KK, Gunn JL, Balar P, Khadela A, Vaghela D, et al. Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes. Cancer Rep (Hoboken). 2023;6(Suppl 1):e1821.

Article  PubMed  Google Scholar 

Wang Y, Feng Z, Zhang Y, Zhang Y. Establishment and verification of a prognostic risk score model based on immune genes for hepatocellular carcinoma in an Asian population. Transl Cancer Res. 2023;12(10):2806–22.

Article  PubMed  PubMed Central  Google Scholar 

Imamura T, Okamura Y, Ohshima K, Uesaka K, Sugiura T, Yamamoto Y, et al. Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas. J Hepatobiliary Pancreat Sci. 2023;30(3):269–82.

Article  PubMed  Google Scholar 

Kim T, Issa D, Onyshchenko M. Analyzing TCGA data to identify gene mutations linked to hepatocellular carcinoma in Asians. Gastrointest Tumors. 2022;9(2–4):43–58.

Article  PubMed  PubMed Central  Google Scholar 

Abenavoli L, Montori M, Svegliati Baroni G, Argenziano ME, Giorgi F, Scarlata GGM, et al. Perspective on the role of gut microbiome in the treatment of hepatocellular carcinoma with immune checkpoint inhibitors. Medicina (Kaunas). 2023;59(8):1427.

Article  PubMed  Google Scholar 

Lyubitelev A, Studitsky V. Inhibition of cancer development by natural plant polyphenols: molecular mechanisms. Int J Mol Sci. 2023;24(13):10663.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahmed S, Khan H, Aschner M, Mirzae H, Küpeli Akkol E, Capasso R. Anticancer potential of furanocoumarins: mechanistic and therapeutic aspects. Int J Mol Sci. 2020;21(16):5622.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rah B, Farhat NM, Hamad M, Muhammad JS. JAK/STAT signaling and cellular iron metabolism in hepatocellular carcinoma: therapeutic implications. Clin Exp Med. 2023;23(7):3147–57.

Article  CAS  PubMed  Google Scholar 

Stagos D, Amoutzias GD, Matakos A, Spyrou A, Tsatsakis AM, Kouretas D. Chemoprevention of liver cancer by plant polyphenols. Food Chem Toxicol. 2012;50(6):2155–70.

Article  CAS  PubMed  Google Scholar 

Li S, Yin S, Ding H, Shao Y, Zhou S, Pu W, et al. Polyphenols as potential metabolism mechanisms regulators in liver protection and liver cancer prevention. Cell Prolif. 2023;56(1):e13346.

Article  CAS  PubMed  Google Scholar 

Yang C, Zhang S, Cheng Z, Liu Z, Zhang L, Jiang K, et al. Multi-region sequencing with spatial information enables accurate heterogeneity estimation and risk stratification in liver cancer. Genome Med. 2022;14(1):142.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xue R, Zhang Q, Cao Q, Kong R, Xiang X, Liu H, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature. 2022;612(7938):141–7.

Article  CAS  PubMed  Google Scholar 

Yu X, Lei X. Application of the multi-omics liquid biopsy method M2P-HCC in early liver cancer screening for high-risk individuals with hepatitis B-related liver cancer. Diagnostics (Basel). 2023;13(15):2484.

Article  CAS  PubMed  Google Scholar 

Wang SH, Yeh SH, Chen PJ. Androgen enhances aflatoxin-induced genotoxicity and inflammation to liver cancer in male hepatitis B patients. Cell Mol Gastroenterol Hepatol. 2023;15(2):507–8.

Article  CAS  PubMed  Google Scholar 

Xia P, Liu DH, Wang D, Wen GM, Zhao ZY. SLC3A2, as an indirect target gene of ALDH2, exacerbates alcohol-associated liver cancer via the sphingolipid biosynthesis pathway. Free Radic Biol Med. 2023;206:125–33.

Article  CAS  PubMed  Google Scholar 

Rodríguez-Lara A, Rueda-Robles A, Sáez-Lara MJ, Plaza-Diaz J, Álvarez-Mercado AI. From non-alcoholic fatty liver disease to liver cancer: microbiota and inflammation as key players. Pathogens. 2023;12(7):940.

Article  PubMed  PubMed Central  Google Scholar 

Adugna A. Histomolecular characterisation of hepatitis B virus induced liver cancer. Rev Med Virol. 2023;33(6):e2485.

Article  CAS  PubMed  Google Scholar 

Dai W, Shen J, Yan J, Bott AJ, Maimouni S, Daguplo HQ, et al. Glutamine synthetase limits β-catenin-mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1. J Clin Invest. 2022;132(24):e161408.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Saitoh S, et al. Favorable impact of serum TERT C228T for prognosis after surgical resection for liver cancer. Oncology. 2023;101(11):738–52.

Article  CAS  PubMed  Google Scholar 

Vu T, Fowler A, McCarty N. Comprehensive analysis of the prognostic significance of the TRIM family in the context of TP53 mutations in cancers. Cancers (Basel). 2023;15(15):3792.

Article  CAS  PubMed  Google Scholar 

Mou H, Eskiocak O, Özler KA, Gorman M, Yue J, Jin Y, et al. CRISPR-induced exon skipping of β-catenin reveals tumorigenic mutants driving distinct subtypes of liver cancer. J Pathol. 2023;259(4):415–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schaeffer S, Gupta B, Calatayud AL, Calderaro J, Caruso S, Hirsch TZ, et al. RSK2 inactivation cooperates with AXIN1 inactivation or β-catenin activation to promote hepatocarcinogenesis. J Hepatol. 2023;79(3):704–16.

Article  CAS  PubMed  Google Scholar 

Lin D, Luo R, Ye Z, Wei Q, Bae H, Juon HS, et al. Genomic characterization of early-stage hepatocellular carcinoma patients with hepatitis B using circulating tumor DNA. Clin Res Hepatol Gastroenterol. 2023;47(7):102161.

Article  CAS  PubMed  Google Scholar 

Tümen D, Heumann P, Gülow K, Demirci CN, Cosma LS, Müller M, et al. Pathogenesis and current treatment strategies of hepatocellular carcinoma. Biomedicines. 2022;10(12):3202.

Article  PubMed  PubMed Central  Google Scholar 

He J, Han J, Lin K, Wang J, Li G, Li X, et al. PTEN/AKT and Wnt/β-catenin signaling pathways regulate the proliferation of Lgr5+ cells in liver cancer. Biochem Biophys Res Commun. 2023;683:149117.

Article  CAS  PubMed  Google Scholar 

Lin W, Wang K, Mo J, Wang L, Song Z, Jiang H, et al. PIK3R3 is upregulated in liver cancer and activates Akt signaling to control cancer growth by regulation of CDKN1C and SMC1A. Cancer Med. 2023;12(13):14413–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

You M, Fu J, Lv X, Wang L, Wang H, Li R. Saikosaponin b2 inhibits tumor angiogenesis in liver cancer via down-regulation of VEGF/ERK/HIF-1α signaling. Oncol Rep. 2023;50(1):136.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ye JC, Hsieh YS, Chen PN, Liu JY, Hsieh YH. Involvement of matrix metalloproteinase 1 and urokinase-type plasminogen activator in the PKCα-p38 MAPK pathway-mediated progression of human liver cancer cells. Drug Dev Res. 2023;84(4):767–76.

Article  CAS  PubMed  Google Scholar 

Yamada K, Hannya Y, Oikawa T, Yoshida A, Katagiri K, Yoshida S, et al. Extended-synaptotagmin 1 enhances liver cancer progression mediated by the unconventional secretion of cytosolic proteins. Molecules. 2023;28(10):4033.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalantari L, Ghotbabadi ZR, Gholipour A, Ehymayed HM, Najafiyan B, Amirlou P, et al. A state-of-the-art review on the NRF2 in Hepatitis virus-associated liver cancer. Cell Commun Signal. 2023;21(1):318.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buttell A, Qiu W. The action and resistance mechanisms of Lenvatinib in liver cancer. Mol Carcinog. 2023;62(12):1918–34.

Article  CAS  PubMed  Google Scholar 

Abusaliya A, Jeong SH, Bhosale PB, Kim HH, Park MY, Kim E, et al. Mechanistic action of cell cycle arrest and intrinsic apoptosis via inhibiting Akt/mTOR and activation of p38-MAPK signaling pathways in hep3b liver cancer cells by prunetrin-A flavonoid with therapeutic potentiaL. Nutrients. 2023;15(15):3407.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Zhu J, Yu Z, Zhai F, Li H, Jin X. Regulation of apoptosis by ubiquitination in liver cancer. Am J Cancer Res. 2023;13(10):4832–71.

CAS  PubMed  PubMed Central  Google Scholar 

Elmetwalli A, Diab T, Albalawi AN, El-Naggar SA, El-Far AH, Ghedan AR, et al. Diarylheptanoids/sorafenib as a potential anticancer combination against hepatocellular carcinoma: the p53/MMP9 axis of action. Naunyn Schmiedebergs Arch Pharmacol. 2023;396(10):2501–17.

Article  CAS